Latest / What If: Science, Theory, and Possibilities
What If You Shrunk Every Second?
Learn more about Gain Therapeutics here.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next-generation allosteric therapies. Gain’s lead drug candidate, GT-02287, is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.
If suddenly…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.